Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 1(6)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07165652Phase 1Completed

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®

Role: lead

NCT06492226Phase 1Completed

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®

Role: lead

NCT05890729Phase 1Recruiting

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Role: lead

NCT06310824Phase 1Completed

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

Role: lead

NCT06627478Phase 1Completed

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

Role: lead

NCT06169397Phase 2Enrolling By Invitation

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Role: lead

NCT06504966Phase 3Withdrawn

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

Role: lead

NCT04971395Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

Role: lead

All 8 trials loaded